




Join Keystone Symposia
for the 2016 conference on:

Antibodies as Drugs

March 6–10, 2016

Fairmont Chateau Whistler | Whistler, British Columbia | Canada

Scientific Organizers:

Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup

Joint with the conference on

Cancer Vaccines Targeting Cancer Genes for Immunotherapy

This meeting will focus attention on many of the key advances in antibody-based technologies as well as on where the field is heading. Some of the critical topics to be covered include: 1) Antibody structure and function; 2) Engineered antibodies and antibody-like molecules for improved efficacy; 3) Antibody pharmacologic properties and biologic distribution; 4) Antibody-based therapies for cancer and infectious diseases; 5) Targeting costimulatory pathways and immunological checkpoints; 6) Antibodies as carriers of drugs, cytokines, radioisotopes and imaging agents; 7) Antibody mimetics; 8) Clinical advancements and challenges. This meeting has become an established forum that attracts both new investigators and leaders in the field, coming from academia, industry and research institutes around the globe. The goals of the meeting will be to address the critical issues facing the broad field of antibody-based therapeutics, provide an overview of recent advances and bring together interdisciplinary groups for the generation of new ideas and promising areas of investigation.

Session Topics:

- Getting Antibodies to Where They Need to Go
- Engineering Antibody Function
- B Cell Biology and Antibody Repertoires
- Novel Antibody Constructs
- Targeted Delivery for Imaging and Therapy
- Antibodies for Checkpoint Blockade (Joint)
- Antibodies as Co-Factors (Joint)
- Antibodies for the Treatment of Infectious Diseases



Submitting an abstract is a great way of participating in the conference through poster presentation and possible selection for a short talk.

Scholarship & Discounted Abstract Deadline: Nov 5, 2015

Abstract Deadline: Dec 8, 2015

Discounted Registration Deadline: Jan 7, 2016

For additional details, visit www.keystonesymposia.org/16X2.

KEYSTONE SYMPOSIA[™]
on Molecular and Cellular Biology

Accelerating Life Science Discovery

www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230

a 501(c)(3) nonprofit educational organization

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs (X2)

Scientific Organizers: Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup

Sponsored by Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.

Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (X1)

Scientific Organizers: A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel

March 6-10, 2016 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada

Sponsored by Regeneron Pharmaceuticals, Inc.

Abstract & Scholarship Deadline: November 5, 2015 / Abstract Deadline: December 8, 2015 / Discounted Registration Deadline: January 7, 2016

SUNDAY, MARCH 6

Arrival and Registration

MONDAY, MARCH 7

Keynote Address

George D. Yancopoulos, Regeneron Pharmaceuticals, Inc., USA

Rakesh K. Jain, Massachusetts General Hospital, USA

Physiological Barriers for Antibody Delivery

Keynote Addresses

Ronald N. Germain, NIAID, National Institutes of Health, USA

Visualizing and Deconstructing Immune Responses In Situ

Sebastian Amigorena, Institut Curie, France

The Makings of Antigen Presentation

Getting Antibodies to Where They Need to Go (X2)

***Peter D. Senter**, Seattle Genetics Inc., USA

Karl Dane Wittrup, Massachusetts Institute of Technology, USA

Macromolecular Based Tumor Targeting: Design Principles

Alison M. Betts, Pfizer Inc., USA

PK/PD Modeling for Macromolecular Drug Delivery

Short Talk(s) Chosen from Abstracts

Antigens (X1)

Cornelis J. M. Melief, Leiden University Medical Center, Netherlands
Cancer Antigens for Cross-Presentation in vivo

Victor H. Engelhard, University of Virginia, USA

Phosphopeptides Displayed by MHC Molecules as New Generation Cancer Vaccine Targets

Short Talk(s) Chosen from Abstracts

Poster Session 1

Workshop 1 (X2)

Short Talks Chosen from Abstracts

Workshop 1: Different Classes and Formulations of Tumor Antigens (X1)

Short Talks Chosen from Abstracts

Engineering Antibody Function (X2)

***Karl Dane Wittrup**, Massachusetts Institute of Technology, USA

Margaret Ellen Ackerman, Dartmouth College, USA

Evolution of Antibodies for Optimized Effector Function Activities

Jeanette H.W. Leusen, University Medical Center Utrecht, Netherlands

Antibodies and Fc Receptors in Cancer and Infection

Sarel J. Fleishman, Weizmann Institute of Science, Israel

De novo Design of Novel Protein Functions

Short Talk Chosen from Abstracts

Antigen-Presenting Cells (X1)

Julie Magarian Blander, Mount Sinai School of Medicine, USA

Regulation of Antigen Cross-Presentation in Dendritic Cells

Laurence Zitvogel, Institut Gustave Roussy, France

Molecular Mechanisms of Cancer Antigen Presentation at the Tumor Site

Matthew F. Krummel, University of California, San Francisco, USA

DCs in Tumor Microenvironment

Short Talk Chosen from Abstracts

TUESDAY, MARCH 8

B Cell Biology and Antibody Repertoires (X2)

Speaker to be Announced

George Georgiou, University of Texas at Austin, USA

Systematic Characterization and Comparative Analysis of Antibody Repertoires

Pavel Tolar, Francis Crick Institute, UK

EMBO Young Investigator Lecture: Regulation of Antibody Responses by B Cell Mechanical Activity

Laura M. Walker, Adimab, USA

High-Throughput Isolation of Novel RSV MAbs from Human B Cells

Short Talk(s) Chosen from Abstracts

Priming Effector T Cells (X1)

Victor Appay, INSERM U1135, France

Induction of High Quality Effector CD8+ T Cells in Humans

Luca Gattinoni, NCI, National Institutes of Health, USA

Generation of Long-Lived Cancer Antigen-Specific CD8+ T Cell Memory

Pamela S. Ohashi, Ontario Cancer Institute, Canada

Molecular Programming of Antigen Presenting Cells for Optimal CD8+ T Cell Immunity

Short Talk(s) Chosen from Abstracts

Workshop 2: Vehicles for Vaccination (X1)

Short Talks Chosen from Abstracts

Novel Antibody Constructs (X2)

***Anna M. Wu**, University of California, Los Angeles, USA

David A. Scheinberg, Memorial Sloan-Kettering Cancer Center, USA
Targeting Undruggable Intracellular Oncoproteins with Antibodies

Dennis R. Benjamin, Seattle Genetics Inc., USA

Antibody Drug Conjugates for Cancer Therapy

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs (X2)

Scientific Organizers: Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup

Sponsored by Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.

Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (X1)

Scientific Organizers: A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel

March 6-10, 2016 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada

Sponsored by Regeneron Pharmaceuticals, Inc.

Abstract & Scholarship Deadline: November 5, 2015 / Abstract Deadline: December 8, 2015 / Discounted Registration Deadline: January 7, 2016

Birgit Schoeberl, Merrimack Pharmaceuticals, USA
Multispecific Antibody Therapeutics Derived from Systems Biology and Computational Modeling

Short Talk Chosen from Abstracts

Reprogramming T Cell Memory (X1)

Rafi Ahmed, Emory University School of Medicine, USA
Features of Memory CD8+ T Cells in Chronic Infection

Nicholas P. Restifo, NCI, National Institutes of Health, USA
Reprogramming CD4+ T Cells

Jonathan D. Powell, Johns Hopkins University School of Medicine, USA
Targeting Immunometabolism as a Means of Enhancing Immunotherapy

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, MARCH 9

Targeted Delivery for Imaging and Therapy (X2)

***Alan J. Korman**, Bristol-Myers Squibb, USA

Anna M. Wu, University of California, Los Angeles, USA
Novel Antibody Constructs for Imaging and Therapy

Andreas G. Plückthun, University of Zürich, Switzerland
Engineered Antibodies and Antibody Scaffolds

Katherine A. Vallis, University of Oxford, UK
Targeted Antibody-Based Radiation Therapy for Cancer

James M. Olson, Fred Hutchinson Cancer Research Center, USA
Tumor Paint and Penetrating Peptide Drug Conjugates

Short Talk(s) Chosen from Abstracts

Cancer Vaccines (X1)

A. Karolina Palucka, The Jackson Laboratory for Genomic Medicine, USA

Dendritic Cells as Cancer Vaccines

Elizabeth M. Jaffee, Johns Hopkins University, USA
Listeria-Based Cancer Vaccines

Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, USA
Oncolytic Virus-Based Melanoma Immunotherapy: Phase III Clinical Trial

Sandra Demaria, Weill Cornell Medical College, USA
In situ Vaccination by Radiation Therapy

Short Talk(s) Chosen from Abstracts

Antibodies for Checkpoint Blockade (Joint)

Alan J. Korman, Bristol-Myers Squibb, USA
Antitumor Activity of Immunomodulatory Antibodies

Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
PD-1 Blockade in Cancer Therapy

Mark J. Smyth, Peter MacCallum Cancer Centre/QIMR Berghofer

Lieping Chen, Yale University, USA
New Targets for Checkpoint Blockade

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, MARCH 10

Antibodies as Co-Factors (Joint)

Madhav V. Dhodapkar, Yale School of Medicine, USA
Talk Title to be Announced

Carl G. Figdor, Radboud University Medical Center / RIMLS, Netherlands
DC-Targeting Vaccines

Ira Mellman, Genentech, Inc., USA
The Mechanistic Basis of Cancer Immunotherapy

Hyam I. Levitsky, Juno Therapeutics, Inc., USA
CD40 Agonist Antibodies - The Ideal Combination Partner in Cancer Immunotherapy

Short Talk(s) Chosen from Abstracts

Workshop 2 (X2)

Short Talks Chosen from Abstracts

Workshop 3: Peptides as Vaccines (X1)

Short Talks Chosen from Abstracts

Antibodies for the Treatment of Infectious Diseases (X2)

***Andreas G. Plückthun**, University of Zürich, Switzerland

Leo James, University of Cambridge, UK
Intracellular Antibody Immunity and the Cytosolic FcR TRIM21

William Schief, IAVI and The Scripps Research Institute, USA
Neutralizing Antibodies by Design or Vaccination

Carole A. Bewley, National Institutes of Health, USA
Talk Title to be Announced

Linking Cancer Genetics and Genomics with Immunity (X1)

Robert D. Schreiber, Washington University School of Medicine, USA
Cancer Specific Mutations as Tumor Rejection Antigens

Catherine Ju-Ying Wu, Dana Farber Cancer Institute, USA
Genomic-Based Vaccine Studies

Jacques F. Blanchereau, The Jackson Laboratory for Genomic Medicine, USA
Meeting Summary

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X2)

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X1)

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs (X2)

Scientific Organizers: Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup

Sponsored by Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.

Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (X1)

Scientific Organizers: A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel

March 6-10, 2016 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada

Sponsored by Regeneron Pharmaceuticals, Inc.

Abstract & Scholarship Deadline: November 5, 2015 / Abstract Deadline: December 8, 2015 / Discounted Registration Deadline: January 7, 2016

Medical Research Institute, Australia

CD96/TIGIT/DNAM Pathway and Tumor Rejection

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs (X2)

Scientific Organizers: Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup

Sponsored by Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.

Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (X1)

Scientific Organizers: A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel

March 6-10, 2016 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada

Sponsored by Regeneron Pharmaceuticals, Inc.

Abstract & Scholarship Deadline: November 5, 2015 / Abstract Deadline: December 8, 2015 / Discounted Registration Deadline: January 7, 2016

FRIDAY, MARCH 11

Departure